The 2026 China-Global Healthcare Investment & Partnership Summit (CHIPS 2026) concluded on October 31 at Tianmu Qintai in Hengqin. The three-day summit drew over 1,000 guests from global healthcare companies, research organizations, and clinical institutions, including those from the Chinese mainland, Hong Kong and Macao, as well as overseas delegates from Europe, the Americas, the Middle East, and Latin America.

The summit focused on frontier innovation and artificial intelligence (AI), with thematic forums covering key areas including oncology and immunology, metabolic health, and medical devices. It released the 2026 China Pharmaceutical Innovation and Invention Index, highlighting the progress and industrial transformation in China’s pharmaceutical innovation.

AI emerged as a key focus. Industry experts discussed how it is reshaping drug discovery, R&D decision-making, clinical development, and commercialization. A public discussion session was also held, where investors and audience members discussed the trajectory of AI technology and its future development.

The summit also placed strong emphasis on converting innovation into practical cooperation. Thematic forums covered global outreach of natural medicines, international market entry, and cross-border financial services. Through project roadshows and one-on-one business meetings, the summit facilitated matchmaking among investors, business development teams, and global partners.

More than 70 innovative projects applied to participate in the summit, and nearly 30 presented at on-site roadshows. Over 20 representatives from industry capital, professional investment institutions and multinational pharmaceutical companies participated in reviews and discussions.